UroGen Pharma Ltd.
URGN
Rank in Stocks
#7474
UroGen Pharma Ltd., a biotechnology company, engages in the development and... UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Share Price
$26.18
Last synced: 2026-11-13
Market Cap
$1.32B
Change (1 day)
-0.80%
Change (1 year)
11.17%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade UroGen Pharma Ltd. (URGN)
Category
Healthcare
Operating Margin for UroGen Pharma Ltd. (URGN)
Operating Margin as of November 2026 TTM: -12.36%
According to UroGen Pharma Ltd.'s latest financial reports, its current operating margin (TTM) is -12.36%. At the end of 2025 the company had an operating margin of -113.73%.
Operating Margin history for UroGen Pharma Ltd. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -12.36% | -89.13% |
| 2025 | -113.73% | 6.23% |
| 2024 | -107.06% | 35.13% |
| 2023 | -79.23% | -35.49% |
| 2022 | -122.82% | -36.07% |
| 2021 | -192.11% | -82.12% |
| 2020 | -1,074.15% | -99.82% |
| 2019 | -608,211.11% | 8,789.12% |
| 2018 | -6,842.20% | 2,697.87% |
| 2017 | -244.55% | -5,474.73% |
| 2016 | 4.55% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -84.19% |
US
|
|
| 33.87% | -102.74% |
US
|
|
| -116.04% | -90.61% |
US
|
|
| 25.57% | -102.07% |
AU
|
|
| 31.23% | -102.53% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about UroGen Pharma Ltd.'s operating margin
What is UroGen Pharma Ltd.'s operating margin?
UroGen Pharma Ltd.'s operating margin is -12.36%, as of Nov 2026.
What was UroGen Pharma Ltd.'s operating margin in 2025?
In 2025, UroGen Pharma Ltd.'s operating margin was -113.73%, compared with -107.06% in 2024.
How has UroGen Pharma Ltd.'s operating margin changed since 2020?
From 2020 to 2025, UroGen Pharma Ltd.'s operating margin was highest in 2023 (-79.23%) and lowest in 2020 (-1,074.15%).
How does UroGen Pharma Ltd.'s operating margin compare with similar companies?
UroGen Pharma Ltd.'s operating margin (-12.36%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.